Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 4 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Caps

How do you think SGEN will perform against the market?

Add Stock to CAPS Watchlist

All Players

468 Outperform
31 Underperform
 

All-Star Players

91 Outperform
8 Underperform
 

Wall Street

11 Outperform
6 Underperform
 

Top SGEN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

LifeScientist (23.82)
Submitted March 02, 2016

good dream for sales and appreciation

PDTBiotech (86.40)
Submitted July 07, 2011

$2.34B for a drug which treats HL and ALCL seems very, very rich, even when taking SGEN's strong balance sheet into account. Very cool platform, but the target for brentuximab vedotin is expressed on a narrow enough set of tumor types to keep this… More

SGEN VS S&P 500 (SPY)

Fools bullish on SGEN are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about SGEN.

Recs

0
Member Avatar Bigsef77 (70.07) Submitted: 10/1/2018 2:51:48 PM : Outperform Start Price: $13.06 SGEN Score: +327.59

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Business Wire Business Wire•October 1, 2018

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
More
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--

-ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy-

-Statistically Significant Improvement Achieved in All Key Secondary Endpoints, Including Overall Survival-

-First Randomized Phase 3 Trial to Show Improvement in Overall Survival in Frontline Peripheral T-Cell Lymphoma-

-Data to be Presented at the 2018 ASH Annual Meeting; Global Regulatory Submissions Planned-

Seattle Genetics, Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. The trial demonstrated a statistically significant improvement in progression-free survival (PFS) of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) versus the control arm, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). ECHELON-2 is a global, randomized, double-blind, multicenter trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), also known as mature T-cell lymphoma (MTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of PTCL. ADCETRIS is currently not approved for the frontline treatment of PTCL.

Recs

0
Member Avatar Horsemonkey (50.20) Submitted: 8/1/2018 12:14:03 AM : Outperform Start Price: $70.60 SGEN Score: +6.06

Seattle Genetics is a first mover in antibody-drug conjugates for treating cancers. Its drug Adcetris was approved in August 2011 and expanded in 2018, to treat Hodgkin's lymphoma and anaplastic large-cell lymphomas. It gets all of its revenue from this one drug but it is doing well growing those sales year over year. Sales are up $95.4 million in the previous quarter, 36% from a year ago.

Recs

0
Member Avatar 1badbeerad (24.15) Submitted: 8/28/2017 8:55:19 PM : Outperform Start Price: $48.40 SGEN Score: +38.94

Great upside. Proven science and waiting for the catalyst.

Leaderboard

Find the members with the highest scoring picks in SGEN.

Score Leader

lloydvon

lloydvon (< 20) Score: +1,436.72

The Score Leader is the player with the highest score across all their picks in SGEN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
lloydvon < 20 8/30/2006 Outperform 1Y $4.48 +1,565.18% +128.46% +1,436.72 1 Comment
Zipsdad < 20 10/4/2006 Outperform 1Y $4.67 +1,497.43% +123.86% +1,373.57 0 Comment
twildstar 93.78 10/11/2006 7/20/2012 Outperform NS $4.93 +1,413.18% +119.48% +1,293.70 0 Comment
vkowalczuk 75.08 10/19/2006 Outperform 1Y $5.10 +1,362.75% +118.32% +1,244.42 1 Comment
RAIDERFAN77 68.08 1/3/2007 7/1/2009 Outperform 1Y $5.27 +1,315.56% +109.26% +1,206.30 0 Comment
SloopJohnB06 26.20 12/26/2006 Outperform 5Y $5.63 +1,225.04% +111.40% +1,113.65 0 Comment
muae1 < 20 12/18/2006 Outperform NS $5.76 +1,195.14% +108.83% +1,086.31 0 Comment
biogirl < 20 1/8/2007 Outperform 3M $6.45 +1,056.77% +111.60% +945.17 0 Comment
opveiby 78.01 1/8/2007 Outperform 1Y $6.46 +1,054.80% +111.56% +943.24 0 Comment
Turkmenbashi 31.38 1/8/2007 Outperform 3Y $6.59 +1,032.02% +110.88% +921.14 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackSunTrustRH 83.45 6/11/2018 Outperform NS $66.94 +11.44% +0.72% +10.72 0 Comment
TrackBarclaysCap 89.26 10/23/2017 Outperform NS $63.94 +16.67% +8.92% +7.75 0 Comment
TrackJimCramer 85.77 11/19/2015 Underperform 3W $43.98 +69.62% +34.48% -35.15 0 Comment
TrackUBS 90.88 7/9/2014 Outperform NS $36.73 +103.10% +42.56% +60.55 0 Comment
TrackWayneRogers 63.28 3/21/2014 Outperform 3M $50.19 +48.64% +50.62% -1.98 0 Comment
TrackCreditSuiss 89.06 11/13/2012 Outperform NS $23.58 +216.37% +103.90% +112.47 0 Comment
TrackCantorFitz 38.04 11/8/2012 Underperform NS $21.70 +70.65% +44.26% -26.39 10/31/2014 @ $37.03 0 Comment
TrackPiperJaff 85.72 7/2/2012 Underperform NS $24.90 +71.97% +52.84% -19.13 10/30/2015 @ $42.82 0 Comment
TrackJimCramer 85.77 6/5/2012 Outperform 3W $20.86 +110.83% +61.58% +49.26 11/19/2015 @ $43.98 0 Comment
tracksummerstree 92.82 10/5/2011 Underperform NS $19.80 +276.77% +149.02% -127.74 0 Comment
TrackNeedham 89.87 5/6/2011 Outperform NS $16.70 +346.71% +107.83% +238.87 0 Comment
TrackBioLogicEqu < 20 3/9/2011 Underperform NS $14.79 +404.39% +111.79% -292.61 0 Comment
TrackCanaccord 67.28 11/2/2010 Underperform NS $14.34 +420.22% +135.16% -285.06 0 Comment
TrackBreanMurray 64.28 11/1/2010 Underperform NS $16.04 +365.09% +135.53% -229.55 0 Comment
trackthinkequity 91.57 9/28/2010 Outperform NS $14.49 +414.84% +145.11% +269.73 0 Comment
trackthinkequity 91.57 8/31/2010 Outperform NS $11.61 +4.05% +7.09% -3.04 9/14/2010 @ $12.08 0 Comment
trackwbbsecuriti < 20 8/4/2010 Underperform NS $12.65 +489.72% +149.22% -340.50 0 Comment
TrackJimCramer 85.77 11/4/2009 Underperform 3W $8.95 +133.13% +23.02% -110.11 6/6/2012 @ $20.87 0 Comment
TrackDeutscheSec 85.82 8/13/2009 Outperform NS $11.25 +563.11% +183.04% +380.07 0 Comment
TrackOppenheimer 69.70 10/27/2008 Outperform NS $8.28 +248.67% +66.68% +181.99 9/7/2012 @ $28.87 0 Comment
TrackRBCCapMkts 85.25 3/19/2008 Outperform NS $8.63 +764.43% +117.88% +646.54 0 Comment
TrackMichaelBrus 90.02 2/14/2008 Outperform 1Y $9.35 +697.86% +116.23% +581.63 0 Comment
TrackJPMorgan 86.97 1/28/2008 Outperform NS $9.34 +34.90% -10.84% +45.75 4/30/2010 @ $12.60 0 Comment
TrackFortisBank < 20 9/21/2007 Outperform NS $11.79 -17.64% -29.70% +12.06 10/2/2008 @ $9.71 0 Comment
TrackWMBlair 77.68 8/21/2007 Outperform NS $11.03 +576.34% +104.06% +472.27 0 Comment
TrackCarisandCo 89.73 3/8/2007 Outperform NS $7.40 +13.78% -6.58% +20.37 3/13/2008 @ $8.42 0 Comment
TrackRBCCapMkts 85.25 1/9/2007 Outperform NS $6.61 +94.99% +10.50% +84.49 10/15/2007 @ $12.89 0 Comment
TrackBofASec 92.60 12/12/2006 Outperform NS $6.17 +503.24% +38.15% +465.09 10/1/2014 @ $37.22 0 Comment
TrackNeedham 89.87 10/25/2006 Outperform NS $4.92 +210.16% -3.55% +213.71 3/31/2011 @ $15.26 0 Comment
TrackNextGen < 20 10/6/2006 Outperform NS $4.95 +272.73% +2.37% +270.35 4/17/2012 @ $18.45 0 Comment

Advertisement